Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Stemline Therapeutics Inc. STML

Healthcare Biotechnology
Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an... see more

Recent & Breaking News (NDAQ:STML)

Shareholder Investigation: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - TORC, STML, KLXE

ACCESSWIRE IA May 4, 2020

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Stemline Therapeutics, Inc. - STML

PR Newswire May 4, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Stemline Therapeutics Inc.

PR Newswire May 4, 2020

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Investors are Encouraged to Contact the Firm - TERP, TORC, STML

ACCESSWIRE IA May 4, 2020

STEMLINE THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

ACCESSWIRE IA May 4, 2020

Stemline Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Stemline Therapeutics, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

PR Newswire May 4, 2020

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Stemline Therapeutics Inc. has obtained a Fair Price in its sale to Menarini Group

PR Newswire May 4, 2020

(STML) Alert: Johnson Fistel Investigates Proposed Sale of Stemline Therapeutics; Are Shareholders Getting a Fair Deal?

PR Newswire May 4, 2020

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

GlobeNewswire May 4, 2020

Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results

GlobeNewswire March 13, 2020

Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020

GlobeNewswire March 11, 2020

Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 26, 2020

STEMLINE THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Stemline Therapeutics, Inc.

PR Newswire February 4, 2020

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

GlobeNewswire January 13, 2020

Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2020

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 10, 2019

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

GlobeNewswire December 6, 2019

Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference

GlobeNewswire November 29, 2019

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

GlobeNewswire November 7, 2019

Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

GlobeNewswire November 6, 2019